- Home
- MODD vs INKT Comparison
MODD vs INKT Comparison
Compare MODD & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- INKT
- Stock Information
- Founded
- MODD 1998
- INKT 2017
- Country
- MODD United States
- INKT United States
- Employees
- MODD N/A
- INKT N/A
- Industry
- MODD Industrial Specialties
- INKT Medicinal Chemicals and Botanical Products
- Sector
- MODD Health Care
- INKT Health Care
- Exchange
- MODD Nasdaq
- INKT Nasdaq
- Market Cap
- MODD 35.5M
- INKT 33.6M
- IPO Year
- MODD N/A
- INKT 2021
- Fundamental
- Price
- MODD $1.10
- INKT $9.03
- Analyst Decision
- MODD
- INKT Strong Buy
- Analyst Count
- MODD 0
- INKT 2
- Target Price
- MODD N/A
- INKT $37.50
- AVG Volume (30 Days)
- MODD 126.9K
- INKT 10.0K
- Earning Date
- MODD 02-13-2025
- INKT 03-18-2025
- Dividend Yield
- MODD N/A
- INKT N/A
- EPS Growth
- MODD N/A
- INKT N/A
- EPS
- MODD N/A
- INKT N/A
- Revenue
- MODD N/A
- INKT N/A
- Revenue This Year
- MODD N/A
- INKT N/A
- Revenue Next Year
- MODD N/A
- INKT N/A
- P/E Ratio
- MODD N/A
- INKT N/A
- Revenue Growth
- MODD N/A
- INKT N/A
- 52 Week Low
- MODD $0.68
- INKT $4.56
- 52 Week High
- MODD $2.65
- INKT $19.00
- Technical
- Relative Strength Index (RSI)
- MODD 57.69
- INKT 53.66
- Support Level
- MODD $1.05
- INKT $7.81
- Resistance Level
- MODD $1.29
- INKT $9.23
- Average True Range (ATR)
- MODD 0.12
- INKT 0.85
- MACD
- MODD 0.04
- INKT 0.11
- Stochastic Oscillator
- MODD 62.75
- INKT 68.66
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.